Skip to content
Use caution Drug recall · FDA · Published March 18, 2013

Roxane Recalls Oxcarbazepine 150mg Due to Subpotent Risk

Roxane Laboratories recalls specific lots of Oxcarbazepine Tablets, 150 mg, due to potential subpotency and lower tablet weights.

🇺🇸 FDA recall #D-343-2014DrugRoxane Laboratories ›
Take action

Contact the company

Recalling firmBoehringer Ingelheim Roxane Inc1809 Wilson Rd · Columbus, OH 43228-9579
✎ GovInfoNow plain-language explainer

Boehringer Ingelheim Roxane Inc is recalling Oxcarbazepine Tablets, 150 mg, because testing revealed out-of-specification assay results. An extended investigation also found the potential for tablets to have lower than expected weight. This means the medication may not contain the correct amount of active ingredient. Read more at govinfonow.com/recall/48272-boehringer-ingelheim-roxane-inc-recalls-oxcarbazepine-tablets-150-mg-packaged.

Source Summary by GovInfoNow · govinfonow.com/recall/48272-boehringer-ingelheim-roxane-inc-recalls-oxcarbazepine-tablets-150-mg-packaged · Updated October 13, 2026 · FDA enforcement record: FDA #D-343-2014

Cite this page

“Roxane Recalls Oxcarbazepine 150mg Due to Subpotent Risk.” GovInfoNow, updated October 13, 2026. https://govinfonow.com/recall/48272-boehringer-ingelheim-roxane-inc-recalls-oxcarbazepine-tablets-150-mg-packaged. Based on FDA recall #D-343-2014 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-343-2014%22&limit=1).

The FDA announced on 2013-03-18 that Boehringer Ingelheim Roxane Inc voluntarily recalled Oxcarbazepine Tablets, 150 mg, due to potential subpotency issues. The agency stated the firm discovered out-of-specification assay results and a potential for lower weight tablets.

How to tell if you have it

  • Brand: Roxane Laboratories
  • Product: Oxcarbazepine Tablets 150 mg
  • NDC 0054-0097-20: 10 x 10 count Unit-Dose Tablets in blisters packaged in a carton
  • NDC 0054-0097-25: 100-count bottle
  • Lot #: 259666A, Exp. MAR 2014
  • Lot #: 259666B, Exp. MAR 2014

The hazard

The hazard is a subpotent drug risk. The firm discovered out of specification results for assay and the extended investigation revealed the potential for lower weight tablets.

Context

GovInfoNow's records show Boehringer Ingelheim Roxane Inc has 12 other recalls on record since 2012-11-05. Other recent recalls of similar products include FUROSEMIDE Tablets USP Recall (2015-09-25), Acarbose 50mg Tablets Recall (2015-04-02), busPIRone 5mg Tablets Recall (2026-04-13), Paxil CR 37.5mg Tablets Recall (2026-08-13), and Levothyroxine Tablets Recall (2026-07-13).

How to tell if you have this one

Check your medication for the following details: Product: Oxcarbazepine Tablets, 150 mg. NDCs: 0054-0097-20 (10 x 10 count unit-dose blisters) or 0054-0097-25 (100-count bottle). Lot Numbers: 259666A or 259666B. Expiration Date: MAR 2014.

  • Brand
    Roxane Laboratories
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check your medication details

    Verify if your Oxcarbazepine Tablets, 150 mg match the NDCs, lot numbers (259666A or 259666B), and expiration date (MAR 2014) listed in the recall.

  2. Contact your healthcare provider

    Speak with your doctor or pharmacist immediately to discuss whether you should continue taking this medication or switch to a different product.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 11 months after the firm started it.

1. Firm started the recall: Mar 18, 201312. FDA classified it Class III: Dec 11, 201323. Published in FDA’s Enforcement Report: Dec 18, 201334. FDA terminated the recall: Feb 12, 2014420132014
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-343-2014 (March 18, 2013) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-343-2014 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 13, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA